Budd-Chiari syndrome pathophysiology: Difference between revisions

Jump to navigation Jump to search
Line 7: Line 7:
== Overview==
== Overview==


==Pathophysiology==
==Pathogenesis==
*Occlusion of at least two hepatic veins leads to Budd-Chiari syndrome. Single hepatic vein occlusion is usually silent.  
*Occlusion of at least two hepatic veins leads to Budd-Chiari syndrome. Single hepatic vein occlusion is usually silent.  
*Obstruction in the venous drainage from liver results in venous congestion causing hepatomegaly.Paitents develop postsinusoidal portal hypertension.
*Obstruction in the venous drainage from liver results in venous congestion causing hepatomegaly.Patients develop postsinusoidal portal hypertension.
*Stasis of blood and congestion cause hypoxic damage of hepatocytes, affecting the liver function.This can result in centrilobular fibrosis, nodular regenerative hyperplasia and ultimately cirrhosis.  
*Stasis of blood and congestion cause hypoxic damage of hepatocytes, affecting the liver function.This can result in centrilobular fibrosis, nodular regenerative hyperplasia and ultimately cirrhosis.  
*Hepatocellular necrosis results from increased sinusoidal pressure.  
*Hepatocellular necrosis results from increased sinusoidal pressure.  
*Budd-Chiari is commonly associated with atrophy of peripheral regions and enlargement of the caudate lobe because blood is directly shunted through it into the inferior vena cava.
*Budd-Chiari is commonly associated with atrophy of peripheral regions and enlargement of the caudate lobe because blood is directly shunted through it into the inferior vena cava.
==Genetics==
*Genes associated with increased expression in the pathogenesis of Budd-Chiari syndrome include:<ref name="pmid16162682">{{cite journal |vauthors=Paradis V, Bièche I, Dargère D, Cazals-Hatem D, Laurendeau I, Saada V, Belghiti J, Bezeaud A, Vidaud M, Bedossa P, Valla DC |title=Quantitative gene expression in Budd-Chiari syndrome: a molecular approach to the pathogenesis of the disease |journal=Gut |volume=54 |issue=12 |pages=1776–81 |year=2005 |pmid=16162682 |pmc=1774794 |doi=10.1136/gut.2005.065144 |url=}}</ref><ref name="pmid24799994">{{cite journal |vauthors=Dragoteanu M, Balea IA, Piglesan CD |title=Nuclear medicine dynamic investigations in the diagnosis of Budd-Chiari syndrome |journal=World J Hepatol |volume=6 |issue=4 |pages=251–62 |year=2014 |pmid=24799994 |pmc=4009481 |doi=10.4254/wjh.v6.i4.251 |url=}}</ref>
**Matrix metalloproteinase 7
**Superior cervical ganglion 10 (SCG10)
**Proliferating cell nuclear antigen gene
**C-MYC oncogene
**Tumor protein p53 gene
*Thrombospondin-1 gene expression is decreased in Budd-Chiari syndrome.
==Gross Pathology==
==Microscopic Pathology==


==References==
==References==

Revision as of 16:30, 9 November 2017

Budd-Chiari syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Budd-Chiari syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Budd-Chiari syndrome pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Budd-Chiari syndrome pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Budd-Chiari syndrome pathophysiology

CDC on Budd-Chiari syndrome pathophysiology

Budd-Chiari syndrome pathophysiology in the news

Blogs on Budd-Chiari syndrome pathophysiology

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Budd-Chiari syndrome pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

Pathogenesis

  • Occlusion of at least two hepatic veins leads to Budd-Chiari syndrome. Single hepatic vein occlusion is usually silent.
  • Obstruction in the venous drainage from liver results in venous congestion causing hepatomegaly.Patients develop postsinusoidal portal hypertension.
  • Stasis of blood and congestion cause hypoxic damage of hepatocytes, affecting the liver function.This can result in centrilobular fibrosis, nodular regenerative hyperplasia and ultimately cirrhosis.
  • Hepatocellular necrosis results from increased sinusoidal pressure.
  • Budd-Chiari is commonly associated with atrophy of peripheral regions and enlargement of the caudate lobe because blood is directly shunted through it into the inferior vena cava.

Genetics

  • Genes associated with increased expression in the pathogenesis of Budd-Chiari syndrome include:[1][2]
    • Matrix metalloproteinase 7
    • Superior cervical ganglion 10 (SCG10)
    • Proliferating cell nuclear antigen gene
    • C-MYC oncogene
    • Tumor protein p53 gene
  • Thrombospondin-1 gene expression is decreased in Budd-Chiari syndrome.

Gross Pathology

Microscopic Pathology

References

  1. Paradis V, Bièche I, Dargère D, Cazals-Hatem D, Laurendeau I, Saada V, Belghiti J, Bezeaud A, Vidaud M, Bedossa P, Valla DC (2005). "Quantitative gene expression in Budd-Chiari syndrome: a molecular approach to the pathogenesis of the disease". Gut. 54 (12): 1776–81. doi:10.1136/gut.2005.065144. PMC 1774794. PMID 16162682.
  2. Dragoteanu M, Balea IA, Piglesan CD (2014). "Nuclear medicine dynamic investigations in the diagnosis of Budd-Chiari syndrome". World J Hepatol. 6 (4): 251–62. doi:10.4254/wjh.v6.i4.251. PMC 4009481. PMID 24799994.

Template:WS Template:WH